Drug Delivery in Chronic Inflammatory Respiratory Diseases

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 2214

Special Issue Editors


E-Mail Website
Guest Editor
DOM-Pulmonary, Allergy, and Critical Care Medicine, 1720 2nd Ave South, BBRB 830, Birmingham, AL 35294-0006, USA
Interests: bacterial proteins; Streptococcus pneumoniae; pneumolysin; chronic obstructive lung disease; prolyl oligopeptidase; poly(prolylprolylglycine)15; exosomes; extracellular vesicles; microRNA

E-Mail Website
Co-Guest Editor
Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA
Interests: immunology; lung; innate immunity; exosomes

Special Issue Information

Dear Colleagues,

I am putting together a Special Issue titled “Drug Delivery in Chronic Inflammatory Respiratory Diseases” that I think may be of interest to you. I invite you to submit a manuscript for consideration and possible publication in this Special Issue of Pharmaceutics. Chronic inflammatory diseases of the lung are a major health burden worldwide, and the need for better treatments and mechanisms to deliver these therapeutics are in high demand.  This Special Issue aims to highlight research into new drug targets for diseases such as asthma, fibrosis, and COPD, among others, as well as novel methods for the delivery and manufacture of these therapies, including nanoparticle delivery via extracellular vesicles.  In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: novel drug discovery, delivery mechanisms (including extracellular vesicle delivery), newly identified targets for drug design, and therapy/treatments for chronic lung inflammation.

I look forward to receiving your contributions.

Dr. Kristopher R. Genschmer
Dr. Camilla Margaroli
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • COPD
  • IPF
  • asthma
  • extracellular vesicles
  • drug delivery
  • inflammation
  • lung disease therapeutics

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

18 pages, 2212 KiB  
Review
Advancing Treatment Strategies: A Comprehensive Review of Drug Delivery Innovations for Chronic Inflammatory Respiratory Diseases
by Junming Wang, Pengfei Wang, Yiru Shao and Daikun He
Pharmaceutics 2023, 15(8), 2151; https://doi.org/10.3390/pharmaceutics15082151 - 17 Aug 2023
Viewed by 1908
Abstract
Chronic inflammatory respiratory diseases, such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis, present ongoing challenges in terms of effective treatment and management. These diseases are characterized by persistent inflammation in the airways, leading to structural changes and compromised lung function. [...] Read more.
Chronic inflammatory respiratory diseases, such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis, present ongoing challenges in terms of effective treatment and management. These diseases are characterized by persistent inflammation in the airways, leading to structural changes and compromised lung function. There are several treatments available for them, such as bronchodilators, immunomodulators, and oxygen therapy. However, there are still some shortcomings in the effectiveness and side effects of drugs. To achieve optimal therapeutic outcomes while minimizing systemic side effects, targeted therapies and precise drug delivery systems are crucial to the management of these diseases. This comprehensive review focuses on the role of drug delivery systems in chronic inflammatory respiratory diseases, particularly nanoparticle-based drug delivery systems, inhaled corticosteroids (ICSs), novel biologicals, gene therapy, and personalized medicine. By examining the latest advancements and strategies in these areas, we aim to provide a thorough understanding of the current landscape and future prospects for improving treatment outcomes in these challenging conditions. Full article
(This article belongs to the Special Issue Drug Delivery in Chronic Inflammatory Respiratory Diseases)
Show Figures

Figure 1

Back to TopTop